ANZCHOG Children’s Cancer Clinical Trials Repository - Australian & New Zealand Childrens Haematology/Oncology Group

The goal of the ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) is to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.

This repository lists clinical trials currently open. If you would like to view trials that are preparing to open, temporarily closed or recently closed you can use the study title or keyword search filter. The information provided should be used in conjunction with advice from health care professionals.

A large number of trials that are run at our children’s cancer centres in Australia and New Zealand are international trials. Further information regarding the clinical trials listed is available on national/ international clinical trial registries such as ANZCTR, clinicaltrials.gov and EU Clinical Trials Register.

Print Open Trial List

Study Title	Protocol ID	Disease (Sub Disease)	Diagnosis Stage	Location	Links	Status	Trial Open Date	Sites	Study Type	Phase	Age Eligibility	ANZCTR	International registry ID's
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones	AALL1631	Leukaemia (ALL)	New diagnosis	NSW / QLD / WA	External Registry ≫	Open	19/04/2018	Treatment	Phase 3	1 year to 21 years at diagnosis		NCT03007147
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)	AALL1731	Leukaemia (ALL)	New diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	15/10/2019	Treatment	Phase 3	1 year to 31 Years		NCT03914625
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy	AALL1732	Leukaemia (ALL)	New Diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	28/10/2019	Treatment	Phase 3	1 Year to 24 Years		NCT03959085
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	AAML1531	Leukaemia	New diagnosis	NSW / VIC / WA / NZ	External Registry ≫	Open	03/11/2015	Treatment	Phase 3	90 days to 4 years		NCT02521493
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)	AAML18P1	Chronic Myeloid Leukaemia	On treatment	VIC / WA	External Registry ≫	Open	15/07/2019	Treatment	Phase 2	up to 25 years		NCT03817398
A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients	ACNS1422	Medulloblastoma	New diagnosis	NSW / WA / SA	External Registry ≫	Open		Treatment	Phase 2	3 years to 22 years at the time of enrollment		NCT02724579
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	ACNS1821	Diffuse Intrinsic Pontine Glioma	Newly diagnosed	QLD	External Registry ≫	Open	05/05/2022	Treatment	Phase 1/2	12 Months to 21 Years		NCT05099003
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor	ACNS2021	Brain and Spinal Tumours	Newly diagnosed	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	04/06/2021	Treatment	Phase 2	3 Years to 30 Years		NCT04684368
Australian Cardio-Oncology Registry	ACOR	All tumour types	Newly diagnosed	NSW / VIC / WA / SA / TAS		Open	01/09/2018	Registry	Not applicable	up t 35 Years
A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors	ACT001-AU-002	Advanced brain tumour Advanced solid tumour	Relapse/refractory	NSW / QLD	External Registry ≫	Open	18/09/2019	Treatment	Phase 1	1 Year to 21 Years	ACTRN12618001934235
Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research	Acute Leukaemia Registry	Leukaemia		NSW / QLD / VIC / WA / TAS		Open	01/04/2019	Registry	Not applicable	Child, Adult, Older Adult
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	AGCT1531	Germ Cell Tumour	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	08/05/2017	Treatment	Phase 3	Various depending on risk group & consult protocol		NCT03067181
Paediatric hepatic malignancy international therapeutic trial (PHITT)	AHEP1531	Hepatoblastoma Hepatocellular carcinoma	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	04/10/2018	Treatment	Phase 2/3	up to 30 Years		NCT03533582
Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	ALLELE (ATA129-EBV-302)	EBV post transplant	Refractory	NSW / VIC / WA	External Registry ≫	Open	29/12/2017	Treatment	Phase 3	no limits		NCT03394365
Key Adverse Events After Childhood Cancer	ALTE03N1	Childhood Malignant Neoplasm	Previously treated	QLD / WA / SA	External Registry ≫	Open	24/03/2004	Observational	Not applicable	up to 21 Years		NCT00082745
Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer	ALTE07C1	All Tumour Types	New diagnosis Relapse/refractory	QLD / VIC / WA / NZ	External Registry ≫	Open	15/09/2008	Psycho-social	Not applicable	3 Years to 21 Years		NCT00772200
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy	ALTE11C2	Leukaemia Lymphoma	Previously treated	WA	External Registry ≫	Open	05/08/2013	Late Effects	Not applicable	no limits		NCT01790152
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study	ALTE15N2	Recurrent Neuroblastoma	Relapse/refractory	WA / NZ	External Registry ≫	Open	05/06/2017	Late Effects	Not applicable	5 Years to 50 Years		NCT03057626
Neuroblastoma Biology Studies	ANBL00B1	Solid tumours (Neuroblastoma)	New diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	06/11/2000	Biology	Biology	5 Years to 50 Years		NCT03057626
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma	ANBL1232	Ganglioneuroblastoma Neuroblastoma	Relapse/refractory	NSW / QLD / WA / SA / NZ	External Registry ≫	Open	28/07/2014	Treatment	Phase 3	up to 18 months		NCT02176967
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma	ANBL1821	Solid tumours (Neuroblastoma)	Relapse/refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	28/05/2019	Treatment	Phase 2	1 Year and older		NCT03794349
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma	ANHL1931	Lymphoma	Newly Diagnosed	NSW / QLD	External Registry ≫	Open	07/06/2021	Treatment	Phase 3	2 Years and older		NCT04759586
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	ANZUP 1302	Germ Cell Tumour	New diagnosis	QLD / NZ	External Registry ≫	Open	01/02/2014	Treatment	Phase 3	11 Years to 45 Years		NCT02582697
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	AOST2031	Osteosarcoma	Newly diagnosed	NZ	External Registry ≫	Open	13/01/2023	Treatment	Phase 3	up to 50 Years		NCT05235165
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML	APAL2020D	Acute myeloid leukemia	Relapsed/refractory	WA	External Registry ≫	Open	01/10/2022	Treatment	Phase 3	29 Days to 21 Years		NCT05183035
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias	APAL2020SC	Leukaemia	Relapsed/refractory	NSW / VIC / NZ	External Registry ≫	Open	30/11/2021	Observational	Not applicable	up to 22 Years		NCT04726241
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study	APEC14B1	All Tumour Types		NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	26/10/2015	Registry	Not applicable	up to 25 years		NCT02402244
Renal Tumors Classification Biology and Banking Study	AREN03B2	Renal tumours	Newly diagnosed	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	27/06/2007	Observational	Not applicable	up to 29 Years		NCT00898365
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	AREN1921	Wilms	New Diagnosis Relapse	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	18/09/2020	Treatment	Phase 2	up to 30 Years		NCT04322318
A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma	ARRAY-162-115	Solid tumours	New diagnosis Relapse/refractory	NSW	External Registry ≫	Open	13/08/2020	Treatment	Phase 1	12 Years to 17 Years		NCT03878719
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia	ASSET	Leukaemia	Previously treated	NSW / VIC / WA / SA / NZ	External Registry ≫	Open	20/08/2015	Registry	Not applicable	up to 18 years
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban	B0661037	Venous Thromboembolism	New Diagnosis Relapse/Refractory	NSW	External Registry ≫	Open	02/08/2018	Treatment	Phase 4	3 Months to 17 Years		NCT02464969
A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling	BLU-285-3101	Solid tumours	Relapse/refractory	NSW / VIC	External Registry ≫	Open	14/10/2022	Treatment	Phase 1/2	2 Years to 17 Years		NCT04773782
Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study	Bu4Day-PK-2016	Haematopoietic Stem Cell Transplant	Newly diagnosed Relapsed/refractory	NSW / QLD / WA	External Registry ≫	Open	29/05/2017	Observational	Pilot	up to 18 years	ACTRN12617000227392
A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma	CA224-069	Lymphoma	Relapsed/Refractory	QLD / WA	External Registry ≫	Open	01/11/2022	Treatment	Phase 1/2	up to 30 Years		NCT05255601
A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma	CAMPFIRE- J1S-MC-JP04	Ewing Sarcoma	Relapsed/refractory	VIC	External Registry ≫	Open	10/09/2022	Treatment	Phase 2	1 Year to 39 Years		NCT05440786
Developing genetically modified TCells for the treatment of paediatric solid tumours	CARTpaedST	Solid tumours	New diagnosis			Open	08/04/2018	Treatment	Phase 1	up to 18 years
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	CCTL019A2205B		Previously treated	VIC	External Registry ≫	Open	02/11/2015	Observational	Not applicable	Child, Adult, Older Adult		NCT02445222
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia	CFZ2008 / 20140106	Acute Lymphoblastic Leukaemia (ALL)	Relapse/refractory	NSW / QLD / VIC / WA	External Registry ≫	Open	10/09/2015	Treatment	Phase 1/2	1 Month to 21 Years		NCT02303821
A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma	CO43810	Non-hodgkin lymphoma	Relapsed/refractory	QLD	External Registry ≫	Open	16/11/2022	Treatment	Phase 1/2	6 Months to 30 Years		NCT05533775
A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion	CONNECT1903	Brain and Spinal Tumours (High Grade Gliomas)	New diagnosis	NSW / QLD / WA	External Registry ≫	Open	08/04/2021	Treatment	Pilot	up to 21 years		NCT04655404
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma	CONNECT1905	Adamantinomatous Craniopharyngioma	Relapsed/refractory	WA	External Registry ≫	Open	19/12/2022	Treatment	Phase 2	1 Year to 25 Years		NCT05233397
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma	CONNECT2108	Adamantinomatous Craniopharyngioma	Relapsed/refractory	WA	External Registry ≫	Open	08/05/2023	Treatment	Phase 2	1 Year to 25 Years		NCT05286788
A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours	D0816C00025	Solid Tumours	Relapsed/refractory	WA	External Registry ≫	Open	01/11/2022	Treatment	Phase 1	0 Years to 18 Years		NCT04236414
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma	DAY101-001 (FIREFLY)	Low-grade Glioma	Relapse/refractory	QLD	External Registry ≫	Open	17/03/2021	Treatment	Phase 2	6 Months to 25 Years		NCT04775485
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository	DIPG	Diffuse Intrinsic Pontine Glioma		QLD / WA / NZ	External Registry ≫	Open	30/06/2012	Registry	Not applicable	Child, Adult, Older Adult		NCT03101813
A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A	EFC16295	Hemophilia A	Recurrent/ refractory	QLD	External Registry ≫	Open	19/02/2021	Treatment	Phase 3	up to 12 years		NCT04759131
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue	HeadStart4	Medulloblastoma PNET	Newly diagnosed	NZ	External Registry ≫	Open	01/09/2015	Treatment	Phase 4	up to 10 Years		NCT02875314
Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies	HoTRODS	Diffuse Pontine Glioma Diffuse Midline Glioma High grade glioma	New Diagnosis Relapse	NSW / WA	External Registry ≫	Open	17/07/2012	Observational	Not applicable	no limits	ACTRN12612001183875
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)(HR-NBL2)	HR NBL2	Neuroblastoma	Newly diagnosed	NSW	External Registry ≫	Open	05/11/2019	Treatment	Phase 3	up to 20 years		NCT04221035
A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available	iMATRIX (GO42286)	Solid tumours	Relapse/refractory	NSW / VIC	External Registry ≫	Open	26/07/2021	Treatment	Phase 1/2	up to 17 Years		NCT04774718
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies	INFORM2 NivEnt	CNS Tumour Solid Tumour	Recurrent/ refractory	NSW / VIC / WA	External Registry ≫	Open	26/07/2019	Treatment	Phase 1/2	6 Years to 21 Years		NCT03838042
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	LCH-IV	Langerhans Cell Histiocytosis	New diagnosis	NSW / QLD / VIC / WA / NZ / TAS	External Registry ≫	Open	14/04/2014	Treatment	Phase 3	up to 18 years		NCT02205762
Liquid biopsies for molecular monitoring of paediatric solid tumours	LIBIO	Solid tumours		NSW		Open	09/04/2019	Biology	Not applicable	up to 25 years
European Low and Intermediate Risk Neuroblastoma – A SIOPEN Study	LINES	Solid tumours(Neuroblastoma)	New diagnosis	NSW / VIC / WA	External Registry ≫	Open	31/05/2019	Treatment	Phase 3	90 days to 18 Years		NCT01728155
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours	LOXO-RET-18036	Brain and Spinal Tumours	Relapse/ refractory	NSW / VIC	External Registry ≫	Open	01/07/2019	Treatment	Phase 1/2	6 months to 21 years		NCT03899792
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	LOXO-TRK-15003	Solid tumours	New diagnosis Relapse/ refractory	NSW	External Registry ≫	Open	11/09/2017	Treatment	Phase 1/2	up to 21 years		NCT02637687
A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A	LTS16294	Hemophilia	Previously treated	QLD	External Registry ≫	Open	23/02/2022	Treatment	Phase 3	Child, Adult, Older Adult		NCT04644575
A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms	M20-429	Indolent Non-Hodgkin Lymphoma	Relapsed/refractory	NSW / VIC / WA	External Registry ≫	Open	29/09/2022	Treatment	Phase 1/2	1 Year to 21 Year5		NCT05206357
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients	MetMED	Medulloblastoma	Previously treated	NSW / VIC	External Registry ≫	Open	28/09/2022	Treatment	Phase 3	7 years to 17 years	ACTRN12622000045718
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma	MK-3475-051	Solid Tumour Lymphoma	Relapse/ refractory	NSW / QLD / VIC	External Registry ≫	Open	04/04/2016	Treatment	Phase 1/2	6 months to 17 years		NCT02332668
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)	NB SCI Registry	Neuroblastoma		NSW / QLD / VIC / WA / SA / TAS	External Registry ≫	Open	01/04/2015	Registry	Not applicable	up to 18 Years		NCT02559804
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib	ON TRK	Solid tumours (NTRK Gene Fusion)		NSW	External Registry ≫	Open	03/04/2020	Observational	Not applicable	no limits		NCT04142437
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma	OZM-063 (LGG Avastin)	Brain and Spinal Tumours(Low Grade Gliomas)	New diagnosis Relapse/ refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	29/05/2018	Treatment	Phase 2	6 months to 18 years old		NCT02840409
Phase 2/3 Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV BKV CMV EBV HHV-6 and JCV Infection and/or Disease in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant.	P-105-202			QLD	External Registry ≫	Open	31/03/2023	Observational	Phase 3	Child, Adult, Older Adult		NCT05305040
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients	P3505	Haematological diseases	New Diagnosis Relapse/Refractory	QLD / VIC	External Registry ≫	Open	17/06/2020	Supportive Care	Phase 1	3 months to 18 years	ACTRN12620000141943
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression	PNOC022	Diffuse Midline Glioma	Newly diagnosed Relapsed/Refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	18/08/2022	Treatment	Phase 1/2	2 Years to 39 Years		NCT05009992
A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation	Ponatinib-1501 /AALL1922	Leukaemia (ALL)	Relapse/ refractory	QLD / VIC / WA	External Registry ≫	Open	21/02/2021	Treatment	Phase 1/2	1 Year to 21 Years		NCT04501614
International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions	PPB DICER	Pleuropulmonary Blastoma		NSW / WA	External Registry ≫	Open	06/12/2015	Registry	Not applicable	Child, Adult, Older Adult		NCT03382158
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients	PREDICT	All tumour types	Newly diagnosed	NSW	External Registry ≫	Open	08/03/2021	Observational	Not applicable	up to 21 years		NCT04903782
PRecISion Medicine for Children with Cancer	PRISM	All Tumour Types	New Diagnosis Relapse/ Refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	05/09/2017	Biology	Biology	up to 21 years		NCT03336931
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation	R3ACT Fungal	Invasive Fungal Disease	Newly diagnosed Relapsed/Refractory	NSW	External Registry ≫	Open	19/08/2019	Treatment	Phase 1	1 Years to 80 Years	ACTRN12618001540202
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma	ReRAD	Brain and Spinal Tumours	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	15/04/2017	Treatment	Phase 2	up to 17 years		NCT03126266
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	RG_13-277 (rEECur)	Solid tumours (Ewings sarcoma)	Relapse/ refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	03/04/2018	Treatment	Phase 2/3	4 years to 50 years	ACTRN12618001825246
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	RG_17-427 (FaR-RMS)	Rhabdomyosarcoma	Relapsed/ refractory	NSW / VIC / WA / NZ	External Registry ≫	Open	17/09/2020	Treatment	Phase 1	no limits		NCT04625907
A multicentre study of SARS-CoV-2 infection in children with cancer immunodeficiency or following stem cell transplant	SARS-CoV-2	All tumour types		NSW / QLD / VIC / WA / SA / NZ / TAS		Open	14/04/2020	Registry	Not applicable	up to 21 Years
Using single-cell RNA-sequencing to identify clonal enrichment in paediatric solid tumours	SCRIPT	Solid tumours		NSW		Open	20/07/2018	Biology	Not applicable	up to 18 years
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group)	Study10	Lymphoblastic leukaemia	Newly diagnosed	NSW	External Registry ≫	Open	15/07/2018	Treatment	Phase 3	up to 17 Years		NCT03643276
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda)	T2017-002	Leukaemia (ALL)	Relapsed/ refractory	NSW	External Registry ≫	Open	12/02/2019	Treatment	Phase 1/2	1 Year to 21 Years		NCT03817320
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy	T2018-001	Leukaemia (ALL) Lymphoma (LLy)	Relapsed/refractory	NSW		Open	01/01/2022	Observational	Not applicable	up to 21 years
Safety and oversight of the individually tailored treatment approach: A novel pilot study	TAILOR	All tumour types	Newly diagnosed Relapsed/Refractory	VIC	External Registry ≫	Open	01/06/2021	Treatment	Pilot	2 Years and older		NCT04801966
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	TAPISTRY	All tumour types	Relapsed/ refractory	NSW / VIC	External Registry ≫	Open	18/01/2021	Treatment	Phase 2	no limits		NCT04589845
A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas	TiNT	Solid tumours (Other Solid Tumour)	Relapsed/ refractory	NSW / QLD / VIC / WA / SA / NZ / TAS	External Registry ≫	Open	01/03/2021	Treatment	Phase 2	3 Months to 25 Years	ACTRN12620001229965
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	TOTAL 17	Leukaemia Lymphoma	Newly diagnosed	VIC	External Registry ≫	Open	01/12/2021	Treatment	Phase 2/3	1 Year to 18 Years		NCT03117751
A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations	TPX-0005-07	Solid tumours	Relapsed/ refractory	NSW / QLD / WA	External Registry ≫	Open	20/03/2020	Treatment	Phase 1/2	up to 25 years		NCT04094610
Precision Medicine for Every Child With Cancer	ZERO2	All tumour types	Newly diagnosed Relapsed/Refractory	NSW	External Registry ≫	Open	16/12/2022	Observational	Not applicable	0 Years to 25 Years		NCT05504772

Study Title

Protocol ID

Disease (Sub Disease)

Diagnosis Stage

Location

Links

Status

Trial Open Date

Trial Close Date

Sites

Study Type

Phase

Age Eligibility

ANZCTR

International registry ID's

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

AALL1631

Leukaemia (ALL)

New diagnosis

NSW / QLD / WA